Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

58.95 -1.17 (-1.95%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 28, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	510,211
Open	60.99
Bid (Size)	58.94 (200)
Ask (Size)	58.98 (200)
Prev. Close	60.12
Today's Range	58.67 - 61.37
52wk Range	38.51 - 85.25
Shares Outstanding	42,600,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

July 13, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline ↗

July 11, 2026

Tarsus Pharmaceuticals (NASDAQ:TARS) said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company...

Via MarketBeat

Performance

YTD	-27.0%	-27.0%
1 Month	-3.8%	-3.8%
3 Month	-3.2%	-3.2%
6 Month	-13.2%	-13.2%
1 Year	+41.2%	+41.2%

More News

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

July 08, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme ↗

July 01, 2026

Via Benzinga

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Beats Q1 Estimates with Explosive XDEMVY Growth But Stock Slips ↗

May 06, 2026

Via Chartmill

TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Passes High-Growth Momentum and Minervini Trend Template Screen ↗

March 02, 2026

Via Chartmill

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Q4 2025 Earnings: Revenue Soars on XDEMVY Sales, But Losses Widen ↗

February 23, 2026

Via Chartmill

Tarsus to Participate in Upcoming Investor Conferences

May 28, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗

May 24, 2026

Via The Motley Fool

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗

May 24, 2026

Via The Motley Fool

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

May 14, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Participate in Upcoming Investor Conferences

May 07, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus (TARS) Q1 2026 Earnings Transcript ↗

May 06, 2026

Via The Motley Fool

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

May 06, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

April 29, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

March 31, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade ↗

March 24, 2026

Via The Motley Fool

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

March 23, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗

March 22, 2026

Via The Motley Fool

Tarsus to Participate in Upcoming Investor Conferences

February 26, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus (TARS) Q4 2025 Earnings Call Transcript ↗

February 23, 2026

Via The Motley Fool

What's going on in today's after hours session ↗

February 23, 2026

Via Chartmill

Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

February 23, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

February 18, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

February 17, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Frequently Asked Questions

Is Tarsus Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Tarsus Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Tarsus Pharmaceuticals, Inc. - Common Stock trade on?

Tarsus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock is TARS on the Nasdaq Stock Market

What is the current price of Tarsus Pharmaceuticals, Inc. - Common Stock?

The current price of Tarsus Pharmaceuticals, Inc. - Common Stock is 58.95

When was Tarsus Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Tarsus Pharmaceuticals, Inc. - Common Stock was at 07/28/26 04:00 PM ET

What is the market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock is 2.51B

How many shares of Tarsus Pharmaceuticals, Inc. - Common Stock are outstanding?

Tarsus Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.